Abstract
Serotonin (5-HT) receptors are part of the G protein-coupled and ligand-gated ion channel families. 5-HT exerts its diverse actions by binding to cell surface receptors which can be classified into seven distinct families (5-HT1 to 5- HT7) according to their structural diversity and mode of action. Some of the 5-HT families are comprised of multiple receptors which share similar structural and mechanistic properties but display very different operational profiles. Evidence continues to mount in support of the important roles of the 5-HT receptors in various neuropsychiatric disorders such as anxiety, depression, schizophrenia, migraine and drug addiction. The 5-HT receptors may also play an important role in obesity, aggression, sexual behaviour and cardiovascular disorders. A number of selective/non-selective 5-HT agonist and antagonist ligands (drugs) have been developed to challenge many of these disease states.
Keywords: 5-Hydroxytryptamine, serotonin, central nervous system (CNS), anti-migraine drugs, G-proteins, 5-HT receptor family
Current Pharmaceutical Design
Title: 5-Hydroxytryptamine (5-HT) Receptor Ligands
Volume: 13 Issue: 25
Author(s): Sean L Kitson
Affiliation:
Keywords: 5-Hydroxytryptamine, serotonin, central nervous system (CNS), anti-migraine drugs, G-proteins, 5-HT receptor family
Abstract: Serotonin (5-HT) receptors are part of the G protein-coupled and ligand-gated ion channel families. 5-HT exerts its diverse actions by binding to cell surface receptors which can be classified into seven distinct families (5-HT1 to 5- HT7) according to their structural diversity and mode of action. Some of the 5-HT families are comprised of multiple receptors which share similar structural and mechanistic properties but display very different operational profiles. Evidence continues to mount in support of the important roles of the 5-HT receptors in various neuropsychiatric disorders such as anxiety, depression, schizophrenia, migraine and drug addiction. The 5-HT receptors may also play an important role in obesity, aggression, sexual behaviour and cardiovascular disorders. A number of selective/non-selective 5-HT agonist and antagonist ligands (drugs) have been developed to challenge many of these disease states.
Export Options
About this article
Cite this article as:
Kitson L Sean, 5-Hydroxytryptamine (5-HT) Receptor Ligands, Current Pharmaceutical Design 2007; 13 (25) . https://dx.doi.org/10.2174/138161207781663000
DOI https://dx.doi.org/10.2174/138161207781663000 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Perspectives in Medicinal Chemistry: Metalloprotein Inhibitors: What Have We Made and What is the Next Step?
Current Topics in Medicinal Chemistry Acetylcholinesterase Imaging: Its Use in Therapy Evaluation and Drug Design
Current Pharmaceutical Design Neuropeptide/Receptor Expression and Plasticity in Micturition Pathways
Current Pharmaceutical Design Epigenomic-Basis of Preemptive Medicine for Neurodevelopmental Disorders
Current Genomics Evaluation of Salivary Melatonin Levels in HIV-positive Patients: A Historical Cohort Study
Reviews on Recent Clinical Trials Five Markers Capable to Identify Passive Smoking Exposure Associated with Endothelial Dysfunction in Healthy Individuals
Current Hypertension Reviews Treating Depression in Coronary Artery Disease and Chronic Heart Failure: What’s new in using Selective Serotonin Re-Uptake Inhibitors?
Cardiovascular & Hematological Agents in Medicinal Chemistry Natural Sourced Inhibitors of EGFR, PDGFR, FGFR and VEGFRMediated Signaling Pathways as Potential Anticancer Agents
Current Medicinal Chemistry Delivery Methods of Camptothecin and Its Hydrosoluble Analogue Irinotecan for Treatment of Colorectal Cancer
Current Drug Delivery Inhibition of Sphingomyelin Hydrolysis: Targeting the Lipid Mediator Ceramide as a Key Regulator of Cellular Fate
Current Medicinal Chemistry Bioactive Peptides in Preventative Healthcare: An Overview of Bioactivities and Suggested Methods to Assess Potential Applications
Current Pharmaceutical Design Pediatric Acute-onset Neuropsychiatric Syndrome and <i>Mycoplasma Pneumoniae</i> Infection: A Case Report Analysis with a Metabolomics Approach
Current Pediatric Reviews Peripartum Cardiomyopathy: Moving Towards a More Central Role of Genetics
Current Cardiology Reviews Endocrine Therapy Resistance: Current Status, Possible Mechanisms and Overcoming Strategies
Anti-Cancer Agents in Medicinal Chemistry Tianeptine: An Atypical Antidepressant with Multimodal Pharmacology
Current Psychopharmacology Therapeutic Strategies in HTLV-I-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP)
Central Nervous System Agents in Medicinal Chemistry Intracellular and Extracellular Aspartic Proteinases of Pathogenic Candida Species: Can their Inhibitors be Further Developed?
Current Enzyme Inhibition Meet Our Editorial Board Member
Current Pharmaceutical Biotechnology Evaluation of microRNA Stability in Plasma and Serum from Healthy Dogs
MicroRNA Bifunctional Anti-HIV/TB Inhibitors: Perspective from In-Silico Design and Molecular Dynamics Simulations
Letters in Drug Design & Discovery